期刊文献+

重组人凝血因子Ⅷ表达质粒的构建及其在HepG2细胞中的表达

Construction and expression of the recombinant plasmid containing BDDhFⅧ in HepG2 cells
下载PDF
导出
摘要 目的:构建含有B区缺失型(△760aa-1639aa)人凝血因子Ⅷ(B domain-deleted human FⅧ,BDDhFⅧ)的真核表达质粒,转染HepG2细胞使其稳定表达人凝血因子Ⅷ。方法:将BDDhFVIII基因片段插入pcDNA4/v5-his空载体中构建重组真核表达质粒,测序正确后电转入HepG2细胞,经Ni-NTA纯化,利用Western blot检测凝血因子Ⅷ在HepG2细胞中的表达,持续培养获得稳定表达BDDhFⅧ蛋白的细胞株。结果:经限制性酶切和测序鉴定均证实重组真核表达质粒pcDNA4/v5-his-BDDhFⅧ成功构建,在转染HepG2细胞后,Western blot检测证实人凝血因子Ⅷ可以在HepG2细胞中正确表达。结论:成功构建了人凝血因子Ⅷ的稳定细胞株,并能在HepG2细胞表达目的蛋白。 Objective: To get stable cell line expressing B domain-deleted human FVIII (BDDhFVIII) by constructing the eukaryotic ex- pression plasmid. Methods: Eukaryotic expression plasmid containing BDDhFVIII was constructed and transfected into HepG2 cells via elec- troporation. The expression and purification of the target protein was detected by Western blot. Results: Results of enzyme digestion and se- quence analysis demonstrated that the gene of BDDhFVIII was correctly inserted into the eukaryotic expression vector pcDNA4/vS-his. Western blot confirmed the successful expression of BDDhFVIII at the protein levels in HepG2 cells. Conclusion: The constructed eukaryotic expression vector was able to generate high level expression of human FVIII in HepG2 cells, thus could construct human blood coagulation FVIII stable cell line successfully.
出处 《中国应用生理学杂志》 CAS CSCD 2012年第3期259-262,共4页 Chinese Journal of Applied Physiology
基金 天津市卫生局科技基金资助项目(09KY33)
关键词 B区缺失型人凝血因子VIII 重组真核表达质粒 重组凝血因子VIII 血友病A BDDhFVIII recombinant eukaryotic expression plasmid rFVIII Haemophilia A
  • 相关文献

参考文献9

  • 1Ponder K P. Gene therapy for hemophilia[ J]. Curren Opin Hematol, 2006, 13(5): 301-307. 被引量:1
  • 2Pipe S W. Recombinant clotting factors [ J ]. Thromb Haemost, 2008, 99(5): 840-850. 被引量:1
  • 3Shen B W, Spiegel P C, Chang C H, et al. The tertiary structure and domain organization of coagulation factor VIII [J]. Blood, 2008, 111(3): 1240-1247. 被引量:1
  • 4Ngo J C, Huang M, Roth D A, et al. Crystal structure of human factor VIII : implications for the formation of the factor IXa-factor VIIIa complex [ J ]. Structure, 2008, 16 (4) : 597-606. 被引量:1
  • 5Musso R. Efficacy and safety of recombinant factor VIII prod- ucts in patients with hemophilia A [ J ]. Drugs Today (Barc), 2008, 44(10): 735-750. 被引量:1
  • 6Saenko E L, Ananyeva N M, Moayeri M, et al. Develop- ment of improved factor VIII molecules and new gene transfer approaches for hemophilia A [J]. Curr Gene Ther, 2003, 3 (1) : 27-41. 被引量:1
  • 7Gan S U, Calne R Y. Gene therapy for hemophilia A [ J]. Discov Med, 2006, 6(35) : 198-202. 被引量:1
  • 8Shapiro A, Gruppo R, Pabinger I, et al. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombi- nant factor VIII (rAHF-PFM) from six clinical studies in pa- tients with hemophilia A[J]. Expert Opin Biol Ther, 2009, 9 (3) : 273-283. 被引量:1
  • 9Batlle J, Villar A, Liras A, et al. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain [J]. Blood Coagul Fibrinolysis, 2008, 19(5) : 333-340. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部